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Abstract: Background: Retinol binding protein 4 (RBP4) carries retinol in plasma, but is also considered
an adipokine, as it is implicated in insulin resistance in mice. Plasma RBP4 correlates with total
cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides, and may confer increased
cardiovascular risk. However, controversy exists about circulating RPB4 levels in type 2 diabetes
mellitus (T2DM) and obesity. Here, we analyzed the relationships of RBP4 and retinol with lipoprotein
subfractions in subjects with and without T2DM. Methods: Fasting plasma RBP4 (enzyme-linked
immunosorbent assay) and retinol (high performance liquid chromatography) were assayed in 41
T2DM subjects and 37 non-diabetic subjects. Lipoprotein subfractions (NMR spectroscopy) were
measured in 36 T2DM subjects and 27 non-diabetic subjects. Physical interaction of RBP4 with
lipoproteins was assessed by fast protein liquid chromatography (FPLC). Results: Plasma RBP4 and
retinol were strongly correlated (r = 0.881, p < 0.001). RBP4, retinol and the RBP4/retinol ratio were
not different between T2DM and non-diabetic subjects (all p > 0.12), and were unrelated to body
mass index. Notably, RBP4 and retinol were elevated in subjects with metabolic syndrome (p < 0.05),
which was attributable to an association with elevated triglycerides (p = 0.013). Large VLDL, total
LDL and small LDL were increased in T2DM subjects (p = 0.035 to 0.003). Taking all subjects together,
RBP4 correlated with total cholesterol, non-HDL cholesterol, LDL cholesterol, triglycerides and
apolipoprotein B in univariate analysis (p < 0.001 for each). Age-, sex- and diabetes status-adjusted
multivariable linear regression analysis revealed that RBP4 was independently associated with large
VLDL (β = 0.444, p = 0.005) and small LDL particles (β = 0.539, p < 0.001). Its relationship with
large VLDL remained after further adjustment for retinol. RBP4 did not co-elute with VLDL nor LDL
particles in FPLC analyses. Conclusions: Plasma RBP4 levels are related to but do not physically
interact with large VLDL and small LDL particles. Elevated RBP4 may contribute to a proatherogenic
plasma lipoprotein profile.
Keywords: retinol binding protein 4; retinol; lipoprotein subfractions; large VLDL; small LDL; Type
2 diabetes mellitus; metabolic syndrome; nuclear magnetic resonance spectroscopy
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1. Introduction
The incidence of the metabolic syndrome (MetS) and Type 2 diabetes mellitus (T2DM) has rapidly
increased in the past few years [1]. Both MetS and T2DM are associated with an increased risk of
cardiovascular disease and reduced life span [2]. Impaired insulin action is a main determinant
responsible for the development of T2DM [3]. Hence, continued attention is being paid to the
pathogenic mechanisms underlying insulin resistance.
Retinol-binding protein 4 (RBP4) is produced by the liver and adipose tissue and transports
retinol (vitamin A) via the circulation to peripheral tissues. However, RBP4 is also considered to
be an adipokine, as it has been implicated in the pathogenesis of insulin resistance [4]. In rodent
studies, Rbp4 overexpression was convincingly shown to enhance insulin resistance, impair insulin
signaling in muscle and induce pathways involved in hepatic gluconeogenesis [4]. Conversely, genetic
deletion of Rbp4 in mice was found to enhance insulin sensitivity [4]. Nonetheless, studies in humans
with obesity, impaired glucose tolerance and T2DM have shown inconsistent results regarding the
associations of these pathologies with circulating RBP4. Initial studies documented that RBP4 levels
were elevated in patients with obesity, impaired glucose tolerance and T2DM, and were correlated with
HbA1c, fasting glucose and insulin [5]. Enhanced RBP4 levels were also observed in obese children,
and (pronounced) weight loss was shown to reduce RBP4 levels in some but not in all studies [6–8].
Likewise, studies reporting potential associations between RBP4 and T2DM were also inconsistent.
Initial studies observed elevated RBP4 levels in T2DM patients [9–11], whereas more recent reports
either detected no abnormalities in RBP4 [12] or even found a negative correlation of RBP4 with
diabetes status [13]. RBP4 is the major carrier of retinol in plasma although not all RBP4 may be
“loaded” with retinol. The RBP4/retinol ratio was found to be elevated in T2DM despite lower RBP4
levels as such [13], and similar observations were made in obese children [14]. The RBP4/retinol ratio
has therefore been advocated to better reflect alterations in obesity and T2DM [13,14].
In contrast to the equivocally reported relationships of circulating RBP4 with obesity,
dysglycemia and insulin resistance, positive relationships of RBP4 with total cholesterol, low
density lipoprotein (LDL) cholesterol and triglycerides have repeatedly and almost invariably been
demonstrated [6,7,12,13,15–17]. Quantification of specific lipoprotein subfractions is increasingly used
to better delineate dyslipidemia in pathological conditions, such as obesity and (pre)diabetes [18–21].
Interestingly, RBP4 associates with small dense LDL particles and oxidized LDL [17,22]. No
data are currently available regarding the relationship of RBP4 with nuclear magnetic resonance
(NMR)-quantified lipoprotein subfractions in adult subjects with and without T2DM, the latter condition
being expected to be characterized by elevated large VLDL and small-sized LDL particles [18,20]. Given
that an increasing number of human studies suggest that elevated plasma RBP4 levels may confer
(subclinical) cardiovascular disease (CVD) risk [15,23–26], it is clinically relevant to more precisely
delineate the association of RBP4 with various lipoprotein subfractions.
Therefore, the present study aimed to determine whether plasma levels of RBP4 and/or retinol
relate to VLDL and LDL subfractions in adults with and without T2DM.
2. Experimental Section
2.1. Subjects
The study protocol was approved by the medical ethics committee of the University Medical
Center Groningen. All participants provided written informed consent and were aged > 18 years. They
were recruited by advertisement in local newspapers. T2DM was diagnosed by primary care physicians
based on fasting plasma glucose ≥ 7.0 mmol/L and/or a non-fasting plasma glucose ≥ 11.1 mmol/L.
Diabetic patients using metformin, sulfonylurea and antihypertensives were included. Insulin use
was an exclusion criterion. A positive history of cardiovascular disease, chronic kidney disease
(estimated glomerular filtration rate < 60 mL/min/1.73 m2 and/or proteinuria), abnormal liver function
tests (transaminases > 3 times the upper reference limit) or thyroid dysfunction (thyroid stimulating
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hormone > 10 or < 0.40 mU/L or use of thyroid function influencing medication), as well as current
smoking and use of lipid lowering drugs was also an exclusion criterion. Blood pressure was measured
after 15 min of rest in the left arm in sitting position using a sphygmomanometer. Body mass index
(BMI in kg/m2) was calculated as weight divided by height squared. Waist circumference was measured
on bare skin between the 10th rib and the iliac crest. The participants were studied after an overnight
fast. Metabolic syndrome (MetS) was defined according to NCEP-ATP III criteria [27]. Three or more
of the following criteria were required for categorization of subjects with MetS: waist circumference
> 102 cm for men and > 88 cm for women; hypertension (blood pressure ≥ 130⁄85 mmHg or use of
antihypertensive drugs); fasting plasma triglycerides ≥ 1.70 mmol/L; HDL cholesterol <1.00 mmol/L
for men and <1.30 mmol/L for women; fasting glucose ≥ 5.60 mmol/l. Insulin sensitivity was estimated
by homeostasis model assessment of insulin resistance (HOMA-IR) applying the following equation:
fasting plasma insulin (mU/L) × glucose (mmol/L)/22.5.
2.2. Laboratory Analysis
Serum and EDTA-anticoagulated plasma samples were stored at −80 °C until analysis. Plasma
glucose was measured shortly after blood collection with an APEC glucose analyzer (APEC Inc., Danvers,
MA, USA). Plasma total cholesterol and triglycerides were measured by routine enzymatic methods
(Roche/Hitachi cat. nos 11,875,540 and 1,187,602, respectively; Roche Diagnostics GmBH, Mannheim,
Germany). HDL cholesterol was assayed by a homogeneous enzymatic colorimetric test (Roche/Hitachi,
cat.no 04713214). Non-HDL cholesterol was calculated as the difference between total cholesterol
and HDL cholesterol. LDL cholesterol was calculated by the Friedewald formula if triglycerides
were <4.5 mmol/L. Apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) were measured
by immunoturbidimetry (Roche/Cobas Integra Tinaquant cat no. 03032566, Roche Diagnostics).
HbA1c was measured by high-performance liquid chromatography (HPLC; Bio-Rad, Veenendaal,
the Netherlands; normal range: 27–43 mmol/mol).
Plasma RBP4 was assayed by enzyme-linked immunosorbent assay (ELISA; R&D Systems; Catalog
Number DRB400). In brief, 96-well plates precoated with anti-human RBP4 monoclonal antibody were
stored at 4 ◦C. After adding 200 µL of 2 vials (11 mL/vial) of a buffered protein solution to each well, 20
µL of sample material was added to each well and left for 1 h at room temperature on a horizontal
orbital microplate shaker (0.12” orbit) set at 500 rpm. This procedure was followed by aspiration and
washing of each well with 400 µL buffered surfactant, repeating the process three times for a total
of four washes. 200 µL of monoclonal antibody specific for human RBP4 conjugated to horseradish
peroxidase were added to each well and incubated for 1 h at room temperature under gentle agitation.
After repeating aspiration/wash as described, 200 µL of Substrate Solution consisting of stabilized
hydrogen peroxide and stabilized chromogen (tetramethylbenzidine) were added to each well and
incubated for 30 min at room temperature under protection from light. The reaction was then stopped
by adding 50 µL of 2 N sulfuric acid; the absorbance was measured at 450 nm, 540 nm and 570 nm.
Plasma retinol levels were analyzed by reverse phase high performance liquid chromatography
(HPLC) as described [28]. Briefly, 50 µL plasma samples were added in antioxidant solutions (2.8 mL)
and vortexed thoroughly for 1 min. Retinol was extracted and deproteinized twice with n-hexane in
the presence of retinol acetate (100 µL, concentration 4 µmol/L) as external standard to assess the level
of recovery after the extraction procedure. Standard curves created from a range of concentrations
of retinol were used to determine absolute serum retinol concentrations. Additionally, two negative
controls (only containing internal standard) and two positive controls (low and high concentrations of
retinol plus internal standard) were included in each series of extractions. Samples were evaporated
under N2 and diluted in 300 µL 100% ultrapure ethanol. Then, 50 µL were injected in HPLC (Waters
2795 Alliance HT Separations Module, Connecticut, USA) for phase separation on a C18 column
(Waters Symmetry C18, dimension 150 × 3.0 mm, particle size 5 µm, Waters Corporation, Milford, MA,
USA) (UV-VIS, dual wavelength, UV-4075 Jasco, Tokyo, Japan). Retinoids in samples were identified by
applying exact retention time of known standards in ultraviolet absorption at 325 nm by HPLC. Finally,
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retinol concentrations were calculated and normalized to final volume. The intra-assay coefficients of
variation (CV) of RBP4 and retinol amount to 5.7–8.1% and 3.6%, respectively.
Lipoprotein separation was performed by fast protein liquid chromatography (FPLC) as described
before [29]. One mL of plasma of four control individuals were subjected to size exclusion gel FPLC
filtration using a Superose 6 column (GE Healthcare, Uppsala, Sweden) at a flow rate of 0.5 mL/min.
Fractions of 500 µL each were collected. Total protein (Bradford), total cholesterol, triglycerides
and RBP4 were determined in the respective lipoprotein fractions by ELISA as detailed above. One
representative FPLC profile is presented.
Lipoprotein particle profiles were determined by nuclear magnetic resonance (NMR) spectroscopy
with the LP3 algorithm (LipoScience, now LabCorp, Morrisville, NC, USA) [30,31]. Very low density
lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) particle classes
and subfractions were quantified from the amplitudes of their spectroscopically distinct lipid methyl
group NMR signals. Diameter range estimates were for VLDL (including chylomicrons if present):
>60 nm to 29 nm, for LDL: 29 nm to 18 nm, and for HDL: 14 nm to 7.3 nm. The VLDL, LDL and HDL
particle concentrations (VLDL-P, LDL-P and HDL-P, respectively) were calculated as the weighted
average of the respective lipoprotein subclasses. The intra-assay CVs for the lipoprotein parameters
are: VLDL-P (11.0%), LDL-P (4.1%), HDL-P (2.0%) and amount to 6.6–27.9%. for the various VLDL,
LDL and HDL subfractions.
2.3. Statistical Analysis
IBM SPSS software (SPSS, version 24.0, SPSS Inc. Chicago, IL, USA) was used for data
analysis. Continuous variables were expressed in means ± SD or medians (interquartile ranges)
in case of not-normally distributed data. HOMA-IR, triglycerides and lipoprotein subfractions were
loge transformed to achieve approximately normal distributions. Between group differences in
variables were determined by T-tests for unpaired data and Chi-square tests where appropriate.
Univariate correlations were determined by Pearson correlation coefficients. Multivariable linear
regression analyses were carried out to disclose the independent relationships of RBP4, retinol and the
RBP4/retinol ratio with either T2DM or MetS. Additionally, multivariable linear regression analyses
were performed to disclose the independent associations with RBP4 and retinol with VLDL, LDL and
HDL subfraction characteristics, each in separate models. Two-sided p-values < 0.05 were considered
statistically significant.
3. Results
Forty-one (41) subjects with T2DM and 37 subjects without T2DM were included. Clinical
characteristics and biochemical data are presented in Table 1. Twenty-nine (29) of the diabetic patients
used glucose-lowering drugs (metformin and/or sulfonylurea). Antihypertensive drugs, particularly
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists and diuretics,
alone or in combination were used by 19 T2DM subjects; none of the non-diabetic subjects were using
antihypertensive drugs. Three non-diabetic women were using estrogens. Other medications were
not taken.
As expected, T2DM subjects were classified with MetS more frequently, had higher blood
pressure, were more obese and had higher glucose and HbA1c levels and had higher HOMA-IR
when compared to non-diabetic controls (Table 1). In general, metabolic control was adequate in
the diabetic patients given an average HbA1c level of 50 mmol/mol. Total cholesterol, non-HDL
cholesterol, LDL cholesterol and apoB levels were not significantly different between diabetic and
non-diabetic individuals. Triglycerides were higher, whereas HDL cholesterol was lower in T2DM
subjects (Table 1). Plasma levels of RBP4, retinol and the RBP4/retinol ratio were not different between
diabetic and non-diabetic subjects (Table 1 and Figure 1A), also not after adjustment for age and sex
(RBP4, p = 0.63; retinol, p = 0.25; RBP4/retinol ratio, p = 0,19, respectively; data not shown). In contrast,
RBP4 and retinol levels were higher in subjects with MetS vs. subjects without MetS (Figure 1B; RBP4:
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41.38 ± 7.98 mg/L in subjects with MetS and 37.48 ± 8.48 mg/L in subjects without MetS, p = 0.041;
retinol: 2.37 ± 0.50 µmol/L in subjects with MetS vs. 2.14 ± 0.46 µmol/L in subjects without MetS,
p = 0.038). As a consequence, the RBP4/retinol ratio was not different between subjects with and
without MetS (17.61 ± 1.73 mg/µmol vs. 17.57 ± 1.91 mg/µmol, respectively, p = 0.78). The associations
of RBP4 and retinol with the presence of MetS remained close to significance after adjustment for age
and sex (retinol: β = 0.223, p = 0.052 and RBP4: β = 0.224, p = 0.051; data not shown). Additionally,
in age- and sex-adjusted multivariable linear regression analysis, RBP4 was independently associated
with elevated triglycerides (β = 0.348, p = 0.013), but not with the other individual MetS components (p
≥ 0.75 for each). Serum retinol levels were not associated with any of the MetS components (p > 0.40 for
each; data not shown). In univariate analysis, RBP4 and retinol were not significantly associated with
HOMA-IR (r = 0.088, p = 0.441 and r = 0.149, p = 0.19, respectively). Furthermore, RBP4, retinol and the
RBP4/retinol ratio were not significantly different between men and women (RBP4: 39.01 ± 8.40 mg/L
in men and 39.43 ± 8.53 mg/L in women, p = 0.83; retinol: 2.29 ± 0.46 µmol/L in men and 2.22 ± 0.51
µmol/L in women, p = 0.57; RBP4/retinol ratio: 17.10 ± 1.77 mg/µmol in men and 17.90 ± 1.80 mg/µmol
in women, p = 0.071).
Table 1. Clinical and laboratory characteristics in 41 subjects with Type 2 diabetes mellitus (T2DM) and
37 subjects without T2DM.
T2DM Subjects (n = 41) Non-DiabeticSubjects (n = 37) p-Value
Age (years) 60 ± 10 52 ± 9 <0.001
Gender (men/women) 19/22 10/27 0.127
Metabolic syndrome (yes/no) 29/12 7/30 <0.001
Systolic blood pressure (mm Hg) 145 ± 20 129 ± 20 0.001
Diastolic blood pressure (mm Hg) 87 ± 9 81 ± 12 0.025
BMI (kg/m2) 29.0 ± 4.9 25.5 ± 4.1 0.001
Waist (cm) 100 ± 14 84 ± 13 <0.001
Glucose (mmol/L) 8.9 ± 2.3 5.6 ± 0.7 <0.001
HbA1c (mmol/mol) 50 ± 9 33 ± 3 <0.001
HOMA-IR (mU mmol/L2/22.5) 4.01 (2.94–6.99) 1.56 (1.13–2.03) <0.001
Total cholesterol (mmol/L) 5.53 ± 0.97 5.65 ± 0.98 0.578
Non-HDL cholesterol (mmol/L) 4.21 ± 1.05 4.06 ± 1.10 0.547
LDL cholesterol (mmol/L) 3.39 ± 0.88 3.46 ± 0.97 0.73
HDL cholesterol (mmol/L) 1.31 ± 0.39 1.59 ± 0.35 0.002
Triglycerides (mmol/L) 1.90 ± 1.60 1.34 ± 0.53 0.021
ApoB (g/L) 0.97 ± 0.24 0.91 ± 0.26 0.324
Apo A-1 (g/L) 1.37 ± 0.26 1.46 ± 0.21 0.080
RBP4 (mg/L) 40.13 ± 8.71 38.33 ± 8.11 0.349
Retinol (µmol/L) 2.33 ± 0.53 2.16 ± 0.43 0.129
RBP4/retinol ratio (mg/µmol) 17.38 ± 1.70 17.82 ± 1.94 0.290
Data are expressed in means ± SD, medians (interquartile range) or numbers. Abbreviations: Apo: apolipoprotein;
BMI: body mass index; HOMA-IR: homeostasis model assessment of insulin resistance; HbA1c: glycated hemoglobin;
HDL: high density lipoproteins; LDL: low density lipoproteins; RBP4: retinol binding protein 4. Differences between
subjects with and without T2DM were determined by T-tests (using loge transformed values in case of not-normally
distributed data) and Chi-square tests where appropriate. LDL cholesterol was calculated in 39 T2DM subjects and
in 36 non-diabetic subjects.
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In univariate regression analysis, RBP4 was strongly correlated with retinol in all subjects
combined, and this relationship did not vary according to diabetes status (Table 3A–C). Plasma retinol
and RBP4 levels strongly correlated in all subjects combined (r = 0.881, p < 0.001), as well as in T2DM
subjects (r = 0.900, p < 0.001) and non-diabetic subjects separately (r = 0.859, p < 0.001) (Figure 2).
In all subjects combined, as well as in T2DM subjects and non-diabetic subjects separately, RBP4 and
retinol were unrelated to age, blood pressure, obesity measures and glycemic control, except for a
positive correlation of RBP4 with age in non-diabetic subjects. Notably, both RBP4 and retinol were
positively correlated with total cholesterol, non-HDL cholesterol, LDL cholesterol, triglycerides and
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apoB levels with essentially similar relationships in T2DM subjects and non-diabetic subjects separately
(Table 3A–C).
Table 3. Univariate relationships of retinol binding protein 4 (RBP4) and retinol with clinical and
laboratory variables in 78 subjects (A), 41 subjects with Type 2 diabetes mellitus (T2DM) (B) and 37
subjects without T2DM (C).




Systolic blood pressure 0.151 0.133





Total cholesterol 0.435 *** 0.399 ***
Non-HDL cholesterol 0.463 *** 0.421 ***
LDL cholesterol 0.384 *** 0.368 ***
HDL cholesterol −0.186 −0.163
Triglycerides 0.391 *** 0.313 **






Systolic blood pressure 0.022 0.026





Total cholesterol 0.376 * 0.321 *
Non-HDL cholesterol 0.425 ** 0.340 *
LDL cholesterol 0.315 * 0.271
HDL cholesterol −0.212 −0.122
Triglycerides 0.415 ** 0.293
ApoB 0.394 * 0.262
ApoA-I −0.150 −0.091
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Table 3. Cont.




Age 0.381 * 0.258
Systolic blood pressure 0.235 0.140





Total cholesterol 0.528 *** 0.555 ***
Non-HDL cholesterol 0.500 *** 0.526 ***
LDL cholesterol 0.514 *** 0.463 **
HDL cholesterol −0.090 −0.096
Triglycerides 0.416 * 0.332 *
ApoB 0.489 *** 0.494 ***
ApoA-I 0.184 0.146
Pearson correlation coefficients are shown. Triglycerides are loge transformed. Abbreviations: BMI: body mass
index; HbA1c: glycated hemoglobin; LDL: low density lipoproteins; HDL: high density lipoproteins. * p < 0.05; ** p
≤ 0.01; *** p ≤ 0.001.
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Figure 2. Correlation of total plasma retinol with retinol binding protein 4 (RBP4) in 41 subjects with
and 37 without type 2 diabetes mellitus. All subjects: r = 0.881, p < 0.001; diabetic subjects: r = 0.900, p
< 0.001; non-diabetic subjects: r = 0.859, p < 0.001.
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With respect to lipoprotein subfractions, we observed positive univariate correlations of RBP4
and retinol with VLDL-P, large and medium VLDL, LDL-P, small LDL and small HDL, but inverse
correlations with large HDL (Table 4A–C). Again, these relationships were mostly similar in T2DM
subjects and non-diabetic subjects separately, although for HDL subfractions these relationships
appeared to be stronger in non-diabetic subjects. In addition, large VLDL (r = 0.537, p < 0.001), small
LDL (r = 0.476, p < 0.001) and large HDL (r = −0.403, p = 0.001) were correlated with HOMA-IR
in all subjects combined. Comparable relationships were found in T2DM and non-diabetic subjects
separately (data not shown).
Table 4. Univariate relationships of retinol binding protein 4 (RBP4) and retinol with lipoprotein
subfractions in 63 subjects; (A): all subjects; (B): 36 subjects with Type 2 diabetes mellitus (T2DM) and
(C): 27 subjects without T2DM.
All Subjects (A) (n = 63) RBP4 Retinol
Total VLDL 0.452 *** 0.381 **
Large VLDL 0.433 *** 0.341 **
Medium VLDL 0.293* 0.248 *
Small VLDL 0.178 0.187
Total LDL 0.398 *** 0.340 **
IDL –0.053 –0.098
Large LDL –0.007 0.118
Small LDL 0.423 *** 0.353 **
Total HDL 0.136 0.126
Large HDL –0.243 –0.258 *
Medium HDL –0.056 –0.010
Small HDL 0.317 * 0.290 *
T2DM Subjects (B) (n = 36) RBP4 Retinol
Total VLDP 0.423 * 0.322
Large VLDL 0.401 * 0.262
Medium VLDL 0.238 0.168
Small VLDL 0.160 0.176
Total LDL 0.255 0.191
IDL –0.227 –0.233
Large LDL –0.079 0.082
Small LDL 0.351 * 0.266
Total HDL 0.016 0.010
Large HDL –0.170 –0.190
Medium HDL –0.004 0.064
Small HDL 0.019 0.002
Non-Diabetic Subjects (C) (n = 27) RBP4 Retinol
Total VLDP 0.487 ** 0.472 *
Large VLDL 0.433 * 0.385 *
Medium VLDL 0.344 0.333
Small VLDL 0.270 0.293
Total LDL 0.529 ** 0.442 *
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All Subjects (A) (n = 63) RBP4 Retinol
IDL 0.309 0.257
Large LDL 0.223 0.301
Small LDL 0.467 * 0.366
Total HDL 0.478 * 0.502 **
Large HDL –0.287 –0.254
Medium HDL –0.027 0.051
Small HDL 0.523 ** 0.476 *
Pearson correlation coefficients are shown. All lipoprotein subfractions are loge transformed. Abbreviations: VLDL:
very low density lipoproteins; LDL: low density lipoproteins; IDL: intermediate density lipoproteins; HDL: high
density lipoproteins. * p < 0.05; ** p ≤ 0.01; *** p ≤ 0.001.
We next performed multivariable linear regression analysis to disclose the extent to which RBP4
and retinol were independently related to VLDL, LDL and HDL subfractions (Table 5). In age-, sex-
and diabetes status-adjusted analysis, RBP4 and retinol were independently related to large VLDL
and small LDL (Table 5, models A and B). RBP4 and retinol were also independently and inversely
associated with large HDL (Table 5, models A and B). When these analyses were additionally adjusted
for the use of metformin, sulfonylurea and antihypertensive medication, the positive relationships
of large VLDL with RBP4 (β = 0.494, p < 0.001) and retinol (β = 0.373, p = 0.003), of small LDL with
RBP4 (β = 0.511, p < 0.001) and with retinol (β = 0.376, p = 0.009), and the inverse relationship of
large HDL with RBP4 (β = −0.416, p = 0.011) and retinol (β = −0.343, p = 0.039) remained statistically
significant. Remarkably, when retinol was added as an independent variable to the model of RBP4 with
VLDL subfractions (Table 5, model A), the relationship of RBP4 with large VLDL remained significant
(β = 0.173, p = 0.022). Conversely, when RBP4 was added as independent variable in the model of
retinol with VLDL subfractions (Table 5, model B), the relation of retinol with large VLDL was lost
(β = −0.091, p = 0.28).
Given the correlation of plasma RBP4 levels with certain subfractions, we also assessed whether
RBP4 may actually physically interact with such lipoprotein particles. Lipoprotein particles, as well as
soluble proteins, were separated by FPLC from freshly-obtained (non-frozen) plasma of non-diabetic
individuals and fractions were analyzed for cholesterol, triglycerides, protein and RBP4 concentrations.
A representative FPLC profile is shown in Figure 3. RBP4 remained undetectable in the VLDL enriched
samples (B1–B9), while very high levels were detected in the fractions with soluble proteins (C2–C10).
Some overlap of RBP4 was detected with HDL-containing samples (B10–C2), but RBP4 was absent in
the peak fraction of HDL (C1), indicating that the overlap is due to co-elution rather than a physical
interaction between RBP4 and HDL. From these experiments, it is concluded that while plasma
levels of RBP4 strongly correlate with certain lipoproteins particles; this occurs in the absence of a
physical interaction.
Table 5. Multivariable regression analyses showing independent relationships of retinol binding
protein 4 (RBP4) and retinol with very low density lipoprotein (VLDL) subfractions (A), low density
lipoprotein (LDL) subfractions (B) and high density lipoprotein (HDL) subfractions (C) in 63 subjects
(36 subjects with and 27 subjects without Type 2 diabetes mellitus).
A VLDL Subfractions Model A Model B
β p-Value β p-Value
Age 0.305 0.027 0.226 0.12
Sex (men vs. women) –0.072 0.57 0.018 0.89
T2DM –0.079 0.60 0.017 0.92
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Table 5. Cont.
B LDL Subfractions Model A Model B
β p-Value β p-Value
Large VLDL 0.444 0.005 0.324 0.046
Medium VLDL 0.044 0.770 0.032 0.84
Small VLDL 0.183 0.13 0.206 0.105
Age 0.306 0.035 0.195 0.19
Sex (men vs. women) –0.180 0.19 –0.099 0.48
T2DM 0.157 0.33 –0.030 0.86
IDL –0.150 0.24 –0.138 0.30
Large LDL 0.106 0.39 0.221 0.090
Small LDL 0.539 <0.001 0.440 0.003
B HDL Subfractions Model A Model B
β p-value β p-value
Age 0.309 0.044 0.257 0.095
Sex (men vs. women) –0.180 0.26 0.006 0.97
T2DM –0.073 0.65 –0.008 0.96
Large HDL –0.336 0.034 –0.323 0.043
Medium HDL 0.145 0.38 0.302 0.073
Small HDL 0.262 0.076 0.254 0.086
β: standardized regression coefficient. All lipoprotein subfractions are loge transformed. IDL: intermediate density
lipoproteins; Models A: RBP4 as dependent variable; Models B: retinol as dependent variable.
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The location of peak fractions of very low density lipoprotein (VLDL), low density lipoprotein (LDL)
and high density lipoprotein (HDL) particles, as well as of the soluble proteins are indicated.
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4. Discussion
This study confirms and extends previous findings [6,7,12,13,16,17], showing that plasma RBP4 is
positively correlated with total cholesterol, non-HDL cholesterol, LDL cholesterol, triglycerides and
apoB in subjects with and without T2DM. The main novel finding is that the plasma concentration
of RBP4 is positively correlated with total VLDL and LDL particles, which appeared to be due
to relationships with large VLDL and small LDL particles. The univariate correlations did not
differ in diabetic and non-diabetic subjects. In multivariable linear regression analysis adjusted for
age, sex, diabetes status and the use of glucose lowering and antihypertensive medication, it was
demonstrated that RBP4 was independently related to large VLDL particles, as well as to small LDL
particles. The current study thus suggests that the positive relationship of RBP4 with (triglyceride-rich)
apoB-containing lipoproteins is attributable to associations with large VLDL and small LDL particles.
Notably, no physical interaction appeared to exist between RBP4 and lipoprotein particles.
In our study, plasma RBP4 levels were not elevated in T2DM subjects, in agreement with earlier
studies [12,13], but in contrast to other reports [5,9–11]. In addition, we did not observe a significant
correlation with insulin resistance as determined by HOMA-IR. However, we did find that RBP4 was
elevated in subjects classifying with MetS, which was attributable to its association with triglycerides.
In comparison, Ingelsson et al. also observed RBP4 elevations in MetS and demonstrated incrementally
higher RBP4 levels with an increasing number of MetS components [15]. Of note, while retinol was
found to be elevated in the subjects categorized with MetS as well, there was no significant relationship
with individual MetS components, and we observed no abnormalities in the RBP4/retinol ratio in
T2DM or MetS. In fact, there was a close correlation of retinol with RBP4 as anticipated [14], which
appeared to be linear over the full range of RBP4 concentrations observed. Taken together, these
findings support the notion that elevated levels of circulating RBP4, rather than retinol, represent the
primary abnormality in MetS.
RBP4 levels were predominantly associated with large VLDL particles, as well as with small LDL
particles, the latter finding being consistent with earlier observations using conventional methods
for lipoprotein subfraction quantification [17]. Given the product-precursor relationships of small
LDL particles with large VLDL [18,32,33], it is conceivable that the relationships of RBP4 with these
specific VLDL and LDL subfractions are interdependent. We also observed an independent and
inverse relationship of RBP4 with large HDL particles. It is well established that HDL cholesterol
is inversely associated with large VLDL, consequent to the process of cholesteryl ester transfer [19].
It was recently shown that large VLDL particles determine an increased cholesteryl ester transfer
in T2DM [20], but it is unclear whether RBP4 could interfere with this process. Of further interest,
RBP4 was associated with large VLDL independent of retinol, but retinol was not associated with
large VLDL independent of RBP4. This suggests that circulating RBP4 rather than retinol is primarily
related to large VLDL particles. In addition, large VLDL and small LDL particle concentrations were
expectedly elevated in T2DM [18,20], again consistent with the concept that large VLDL and small LDL
particles are metabolically interrelated [33]. Since our study neither showed an effect of the diabetic
state on plasma RBP4 nor on retinol, we surmise that circulating levels of RBP4 and retinol do not to a
considerable extent explain the predominance of large VLDL and small LDL particles in this condition.
Furthermore, large VLDL and small LDL particles were correlated with HOMA-IR whereas RBP4
and retinol were not. Circulating RBP4 and VLDL particles largely originate from the liver, but their
hepatic production and secretion machineries appear not interconnected. Still, the correlation between
the circulating levels led us to determine whether a possible physical interaction between RBP4 and
VLDL and (small) LDL particles exists. FPLC was used to separate lipoprotein particles from soluble
proteins as a mild approach to retain protein-protein and protein-lipid interactions. Still, no co-elution
of RBP4 with VLDL was observed, providing no evidence that such physical interaction actually exists.
We, therefore, hypothesize that RBP4 could directly interfere with the metabolism of triglyceride-rich
apoB-containing lipoproteins. As a potential mechanism, it is of interest that RBP4 transcriptionally
enhances CD36 expression [26], a protein that impairs VLDL secretion from mouse liver in vivo [34].
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While the current study was primarily focused on RBP4, our findings with respect to retinol levels
are also relevant. Retinol is the circulating form of vitamin A that is locally (in tissues) converted to
retinoic acids (such as all-trans retinoic acid and 9-cis retinoic acid) that activate transcription factors
(Retinoic Acid Receptor (RAR) and Retinoic X Receptor (RXR)) [35,36]. Retinol and retinoic acids
simulate hepatic RBP4 secretion and enhance de novo lipogenesis in the liver [34]. In line, retinoic
acids also stimulate VLDL secretion in rats [37]. More recently, the enzyme 17-beta hydroxysteroid
dehydrogenase 13 (HSD17b13) with retinol dehydrogenase activity, was implicated in the pathogenesis
of non-alcoholic fatty liver disease [38]. Retinol may, therefore, play multiple roles in hepatic fat
accumulation and triglyceride metabolism, both directly and indirectly, by interacting with RBP4.
In view of the accumulating though sometimes controversial epidemiological evidence indicating
that RBP4 is associated with incident CVD [23,24,26,39,40], the present findings with regard to the
association of RBP4 with small LDL particles are likely to be clinically relevant. Small dense LDL
particles are prone to oxidative modification [17] and may predict incident CVD beyond conventional
lipid measures [41–43]. Moreover, smaller-sized LDL particles may be more electronegatively charged
and upregulate the lectin-like oxidized LDL receptor in vitro, a pro-atherogenic phenomenon [44].
Such particles are associated with the extent and severity of coronary artery atherosclerosis [45]. We,
therefore, propose that the relationship of RBP4 with small LDL particles could contribute to its alleged
pro-atherogenic potential.
Several methodological issues of the present study need consideration. Diabetic subjects using
insulin and lipid lowering were not allowed to participate, in order to obviate confounding due to
effects of insulin and lipid-lowering drugs on glucose and lipid metabolism. As a consequence, T2DM
subjects with rather mild hyperglycemia and dyslipidemia were preferentially included, which could
to some extent mask relationships of RBP4 with dysglycemia and could underestimate relationships of
RBP4 with (apo)lipoproteins and lipoprotein subfractions. Furthermore, we excluded subjects with
impaired glomerular filtration rate. This was done to minimize confounding with respect to circulating
RBP4 due to chronic kidney disease in view of the inverse relationship of RBP4 with glomerular
filtration rate [15]. Obviously, the cross-sectional design of our study precludes to establish cause-effect
relationships with certainty. Finally, we consider the present findings as preliminary in view of the
rather low numbers of diabetic and non-diabetic participants included.
5. Conclusions
Serum RBP4 levels are related to large VLDL and small LDL particles, but in the absence of
a physical interaction between RBP4 and the lipoprotein particles. Higher RBP4 may be part of a
proatherogenic plasma lipoprotein profile. However, it seems unlikely that alterations in circulating
RBP4 per se contribute significantly to the predominance of large VLDL and small LDL in the
diabetic state.
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